Summary Of 297 patients with metastatic testicular and extragonadal germ cell tumours (GCT), bone involvement was detected clinically in 3% (7/251) of those at first presentation and in 9% (4/46) of relapsed cases. This difference was not statistically significant (95% confidence limits -2%; +14%). Concurrent systemic metastases, commonly involving lung (7/11 cases) and para-aortic lymph nodes (6/11), were present in all patients with bone disease. All affected patients had localized bone pain and lumbar spine was the most frequent site involved (9/11). Spinal cord compression occurred in two patients while a third developed progressive vertebral collapse after chemotherapy and required extensive surgical reconstruction. At median follow-up of 4 years, survival among patients presenting with bone disease (6/7) was similar to overall survival in the whole group (84%) and appeared better than in those with liver (18/26, 69%) or central nervous system (6/9) metastases at presentation.
Bone is an uncommon site for metastases from testicular and extragonadal germ cell tumours (GCT) (Pugh, 1982) . The large study of Dixon & Moore (1953) described metastases seen in 1,000 testicular GCT affecting United States servicemen to January 1948. Autopsy-proven bony metastases were seen in 21% of GCT containing mainly embryonal carcinoma and 36% of those with predominant teratoma but not in other histologic types. Bones of the trunk were involved most commonly. Mostofi (1973) reported 6,000 testicular tumours on the American Registry of Pathology over 25 years and noted a similar distribution of osseus metastases. These pathologic series largely predated the considerable recent advances in treatment of GCT and in methods for demonstrating bone metastases radiologically during life. With optimal radiotherapeutic techniques in seminoma, very high overall cure rates have been possible for over 20 years (Ball et al., 1982; Duncan & Munro, 1987; Hay et al., 1984) . Isotope bone scans, computerized tomography (CT) and, most recently, magnetic resonance imaging (MRI) have provided much more sensitive means for diagnosing bone involvement than plain radiographs. Johnson et al. (1976) reported an autopsy series of testicular GCT where 47% of bony metastases were seen among seminoma patients, significantly more than in all other histologic subtypes. Bredael et al. (1982) showed similar results in another postmortem series. This apparent change in metastatic pattern from the older series may reflect radiotherapy-induced modification of seminoma natural history with retroperitoneal disease controlled but late recurrence occurring in other sites, including bone, and leading to subsequent death. Now, long term remission and cure in non-seminomatous GCT is common due to widespread use of cisplatin-based combination chemotherapy (Bosl et al., 1986; Logothetis et al., 1986; Newlands et al., 1986; Williams et al., 1987) . Such chemotherapy has also proved effective first-line management for bulky metastatic seminoma and as salvage treatment for seminoma patients relapsing after radiotherapy (Loehrer et al., 1987; Stanton et al., 1985) .
Bone involvement at presentation with GCT is an adverse prognostic feature equivalent to liver or central nervous system (CNS) metastases according to most authors (Bosl et al., 1986; Logothetis et al., 1986; Williams et al., 1987 GCT in recent textbooks of Oncology or Urology are brief (Barzell & Whitmore, 1979; Einhorn et al., 1985; Garnick et al., 1982; Pugh, 1982) and only anecdotal reports of bony metastases from testicular and extragonadal GCT exist (Collis & Eckert, 1985; Gay et al., 1985; Hermann, 1986; Martini et al., 1974; Richardson et al., 1981; Sagalowsky et al., 1986) , mostly referring to seminoma. The incidence of clinically detectable osseous metastases, responsiveness of such metastases to currently available chemotherapy, and long term prognosis in patients with bone involvement from GCT remain poorly defined. This paper analyses 10 years' single institution experience with bone metastases from GCT in an attempt to address these issues and describes some unique management problems which arose in affected patients.
Patients and methods
Records from 297 male patients treated for metastatic GCT of testicular or extragonadal origin between 1977 and 1987 were examined. Most received first-line chemotherapy for non-seminomatous GCT but some were referred for salvage chemotherapy after relapse and others with advanced seminoma were treated primarily using chemotherapy. Histologic sub-types included seminoma, malignant teratoma undifferentiated (MTU), malignant teratoma intermediate (MTI), malignant teratoma trophoblastic (MTT), and malignant teratoma differentiated (MTD) according to British Testicular Tumour Panel Criteria (Pugh, 1976) . All patients underwent regular measurement of serum tumour markers alpha foetoprotein (AFP) and human chorionic gonadotrophin (hCG) as well as serum calcium and alkaline phosphatase. Chemotherapy was administered according to the POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) protocol (Newlands et al., 1986) or a weekly salvage regimen EP/OMB (etoposide 150mg m -2 intravenously (i.v.) plus cisplatin 75 mg m -2 i.v. alternating with vincristine 1 mg m -2 i.v., methotrexate 300 mgm-2 i.v. over 12h and bleomycin 30mg i.v. over 48 h).
Bone involvement was diagnosed on the basis of symptoms, usually pain, plus bone destruction demonstrated using one or more imaging technique including plain radiographs, CT scan, isotope bone scan, and magnetic resonance imaging (MRI). Bone biopsy for histologic confirmation was performed in a majority of cases.
Results
Osseus involvement was noted in 11 cases. Among patients not treated previously, 7 of 251 (3%) had bone disease at presentation and their characteristics are shown in Table I . Most histologic subtypes of GCT were represented in the group with bony involvement. Median follow-up for all nonpretreated patients is 4 years (range one week to 10.8 years) and survival among those with bone involvement (6/7, 86%) was similar to the whole group (84%). By contrast, poorer overall survival was seen among patients with liver metastases at presentation (18/26, 69%) and those with CNS disease at presentation (6/9, 67%). Four of 46 patients (9%) developed bony metastases as part of systemic relapse of their non-seminomatous GCT. Two of these have succumbed despite further treatment.
Coincident metastatic disease elsewhere was noted in all patients with bone involvement, commonly lung (7/11 cases) and para-aortic lymph nodes (6/11). The predominant site of bony involvement was lumbar spine (9/11). Other sites affected were ribs (one case) and skull (two cases) but only two patients had more than one bony site involved concurrently. All patients with bone disease had localized pain. One patient had spastic paraplegia from spinal cord compression at diagnosis, one developed early cord compression after commencing treatment, and a third sustained this complication at relapse. Results of various imaging methods were: plain radiographs showed local bone destruction in 4 of 11 patients, CT scans were positive in 7 of 8 cases with appropriate images obtained, 4 of 6 bone scans performed were positive, and MRI was diagnostic in all three patients who had the investigation performed. Histologic confirmation of osseus metastasis was obtained in 5 cases and changes compatible with necrotic GCT were seen in a sixth patient who had lumbar vertebral biopsy taken at post-chemotherapy retroperitoneal lymphadenectomy. Improvement 
vertebral metastases, massive para-aortic lymphadenopathy, lung metastases and mediastinal involvement from testicular MTU. He was treated with POMB/ACE chemotherapy (Newlands et al., 1986) and had a rapid response in the tumour but progressive vertebral collapse occurred, threatening spinal cord compression (Figure 1 1973). Longstanding associated radiographic changes reflect the slow rate of bone healing and some of these abnormalities may be permanent.
Survival among our patients presenting with bone disease, was similar to the whole group and appeared better than in those with liver or CNS metastases at presentation. These data suggest osseus metastases may not confer such an adverse prognosis as is commonly believed (Bosl et al., 1986; Einhorn et al., 1985; Logothetis et al., 1986; Williams et al., 1987; Bajorin et al., 1988) .
Unfortunately, not all cases of bony involvement described were confirmed histologically. Bone biopsy was undertaken only after careful consideration of potential management implications in each case or if other surgical intervention was necessary. Blood supply to lumbar vertebra may well be compromised by bulky retroperitoneal lymphadenopathy and lead to bone infarction. The possibility that ischaemic necrosis may be the underlying pathology of the collapse of vertebra in some of these patients is the reason we have referred to bone disease in these patients where true bone metastases may not always be present. CT or isotope bone scanning will not distinguish metastatic tumour from bone infarction. However, bone scan abnormalities in all our patients with very bulky retroperitoneal disease did show several 'hot spots' including some in vertebrae not immediately adjacent to the para-aortic node masses, more suggestive of metastatic disease. Even if some of the lumbar vertebral abnormalities observed were due to infarction, their causation remains intimately disease-related if due to vascular compression by adjacent retroperitoneal tumour.
Back pain is a well described presenting complaint in metastatic GCT (Cantwell et al., 1987) , usually due to paraaortic lymph node enlargement. Even though bone disease is rare, our patient with paraplegia from lumbar spine metastases, but with minimal associated retroperitoneal lymphadenopathy, illustrates the importance of considering osseus involvement, especially if bony tenderness is present. As most patients with GCT are young, even minor abnormalities on plain radiographs must be regarded as suspicious. Because GCT are so sensitive to cisplatin-based chemotherapy, rapid tumour lysis may lead to progressive bone destruction after initiation of treatment as illustrated by our patient with lumbar vertebral collapse in such circumstances. Patients with large areas of bone destruction need careful management after commencing chemotherapy to prevent spinal cord compression developing. Even after successful completion of therapy, slow bone healing may result in a persisting tendency to easy fracture as in our patient with crush fracture after coughing several months post-treatment.
Although bone disease seemed more frequent among relapsed GCT patients, it was still uncommon and we did not see isolated bone relapse. Histologic confirmation should be obtained before ascribing solitary osseus lesions to relapse in patients previously treated for GCT as illustrated by our patient with mycobacterial bone disease.
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